Shares of Sophiris Bio Inc. (NASDAQ:SPHS) have earned a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy rating.
Brokerages have set a 12-month consensus price target of $6.75 for the company and are predicting that the company will post ($0.09) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Sophiris Bio an industry rank of 98 out of 265 based on the ratings given to related companies.
SPHS has been the topic of several research analyst reports. Maxim Group boosted their target price on Sophiris Bio from $4.00 to $6.00 and gave the stock a “buy” rating in a research note on Wednesday, August 10th. Echelon Wealth Partners reiterated a “buy” rating and set a $5.00 price target on shares of Sophiris Bio in a research note on Friday, June 10th. Roth Capital assumed coverage on Sophiris Bio in a research note on Thursday, September 15th. They set a “buy” rating and a $8.00 price target on the stock. Finally, Piper Jaffray Cos. assumed coverage on Sophiris Bio in a research note on Tuesday, August 30th. They set an “overweight” rating and a $7.00 price target on the stock.
Sophiris Bio (NASDAQ:SPHS) traded down 3.667% during mid-day trading on Wednesday, hitting $3.179. The company had a trading volume of 669,814 shares. The company has a 50-day moving average price of $3.66 and a 200 day moving average price of $2.47. Sophiris Bio has a 12 month low of $0.67 and a 12 month high of $8.55. The firm’s market capitalization is $71.90 million.
A hedge fund recently raised its stake in Sophiris Bio stock. Citadel Advisors LLC increased its stake in shares of Sophiris Bio Inc. (NASDAQ:SPHS) by 65.2% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 49,176 shares of the biopharmaceutical company’s stock after buying an additional 19,402 shares during the period. Citadel Advisors LLC owned about 0.23% of Sophiris Bio worth $106,000 at the end of the most recent quarter. 5.29% of the stock is owned by hedge funds and other institutional investors.
About Sophiris Bio
Sophiris Bio, Inc, formerly Protox Therapeutics Inc, is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sophiris Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.